Mission

ICER's mission is to lead innovation in comparative effectiveness research through methods that integrate considerations of clinical benefit and economic value.  Through a unique collaboration with patients, clinicians, manufacturers, insurers and other healthcare stakeholders, ICER develops tools to support patient decisions and medical policy that share the goal of achieving maximum value for every healthcare dollar.

TwitterLinkedinFacebookFeed
Brachytherapy/Proton Beam Therapy for Clinically Localized, Low-Risk Prostate Cancer

Stakeholder groups invited to participate:

 

Clinical Organizations:

  • American Society for Therapeutic Radiology and Oncology (ASTRO)
  • American College of Radiology (ACR)
  • Amercian Society of Clinical Oncology (ASCO)
  • American Urological Association (AUA)

 

Patient Advocacy Organizations:

  • American Cancer Society (ACS)
  • Us Too International (USTOO)

 

 

Final Appraisal Documents 

Final Appraisal Document: Brachytherapy and Proton Beam Therapy for Treatment of Clinically Localized, Low-Risk Prostate Cancer

Executive Summary: Brachytherapy and Proton Beam Therapy for Treatment of Clinically Localized, Low-Risk Prostate Cancer 

Mid-Cycle Review Documents 

Economic Model of Multiple Radiation Therapy Treatments for Low-Risk Prostate Cancer: Overview

Systematic Review of Brachytherapy & Proton Beam Therapy for Low-Risk Prostate Cancer: Preliminary

Background Materials & Key Questions

Brachytherapy Overview 

Proton Beam Therapy Overview 

Brachytherapy/Proton Beam Therapy Scoping Committee Call Agenda and Key Questions

Brachytherapy/Proton Beam Therapy Scoping Committee Call Summary

Brachytherapy/Proton Beam Therapy Evidence Review Group

 

 

Comments
Add New Search
Herbert A. Klein, M.D., Ph.D.  - Clinical Professor Radiology, U. of Pittsburgh   |24.3.147.xxx |2009-08-19 02:32:08
Can you please help me home in on references to substantiate the statement on p.
10 of the executive summary that PBT involves greater radiation exposure outside
the prostate than does brachytherapy?
Thank you very much.
Reply
Victor Muñoz-Garzón  - Head of Radiation Oncology (CHUVI_Vigo) Spain   |85.56.197.xxx |2009-09-17 09:37:16
We use IMRT , 3DCRT and Brachytherapy , but no PBT. However brachytherapy is the
closest (conformal) possible radiation ,not in vain, Brachytherapy is from
"inside", perhaps that fact is enough for any more external radiation
dose to any tissue outside the prostate.
Reply
Richard Vance - BSE, MBA, Pati  - Brachytherapy delivers high dose to uretha   |.xxx |2010-03-24 10:20:41
Since the radioactive seeds are implanted inside and throughout the prostate and
remain there I thought the fact of high ionizing radiation to the urethra should
have been discussed and scored. It appears that both external radiation and
Proton radiation provides significantly (by far) less radiation to the urethra
than Brachytherapy. This is a Significant quality of life issue that appears to
have been downgraded in importance.
Reply
victor Munoz-Garzón  - Head of Radiation Oncology (CHUVI_Vigo) Spain   |217.124.245.xxx |2009-08-20 00:11:34
HDR brachytherapy is a excellent treatment for low risk prostate cancer . There
are a lot of papers , even random trials (benjamin guix , Barcelona etc)or
comparision pair to pair HDR vs LDR (Alvaro Martinez , WBH Detroit ). HDR is
also much cheaper, so it does not mean not to defend its use (except for
business reasons) or at least so some reviews as UpToDate ...etc. they give the
scientific value that it deserves.
Sincerely
Victor
Reply
Write comment
Name:
Email:
 
Title:
Please input the anti-spam code that you can read in the image.

3.26 Copyright (C) 2008 Compojoom.com / Copyright (C) 2007 Alain Georgette / Copyright (C) 2006 Frantisek Hliva. All rights reserved."